Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Buy
68
ENFN Quote, Financials, Valuation and Earnings
Last price:
$11.09
Seasonality move
:
-12.46%
Day range:
$11.03 - $11.10
52-week range:
$7.83 - $11.80
Dividend yield:
0%
P/E ratio:
369.00x
P/S ratio:
6.56x
P/B ratio:
14.33x
Volume:
700.6K
Avg. volume:
1.1M
1-year change:
19.03%
Market cap:
$1B
Revenue:
$201.6M
EPS (TTM):
$0.03
Analysts' Opinion
-
Consensus RatingEnfusion has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $10.93, Enfusion has an estimated downside of -1.28% from its current price of $11.07.
-
Price Target UpsideAccording to analysts, the highest upside price target is $11.25 representing -100% upside increase from its current price of $11.07.
Fair Value
-
According to the consensus of 6 analysts, Enfusion has -1.28% downside to fair value with a price target of $10.93 per share.
ENFN vs. S&P 500
-
Over the past 5 trading days, Enfusion has underperformed the S&P 500 by -1.69% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Enfusion does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enfusion has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Enfusion reported revenues of $52.9M.
Earnings Growth
-
Enfusion earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Enfusion reported earnings per share of --.
Enterprise value:
1B
EV / Invested capital:
10.26x
Price / LTM sales:
6.56x
EV / EBIT:
165.93x
EV / Revenue:
5.07x
PEG ratio (5yr expected):
--
EV / Free cash flow:
42.93x
Price / Operating cash flow:
55.61x
Enterprise value / EBITDA:
57.03x
Gross Profit (TTM):
$136.7M
Return On Assets:
2.28%
Net Income Margin (TTM):
1.4%
Return On Equity:
3.17%
Return On Invested Capital:
3.17%
Operating Margin:
2.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $150.3M | $174.5M | $201.6M | $46.5M | $52.9M | |
| Gross Profit | $103.2M | $116.9M | $136.7M | $30.9M | $36.5M | |
| Operating Income | -$12M | $11.9M | $6.2M | $2.1M | $1.6M | |
| EBITDA | -$5.6M | $21.9M | $17.9M | $5.6M | $4.8M | |
| Diluted EPS | -$0.10 | $0.08 | $0.03 | $0.01 | -- | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $28.9M | $89.7M | $96.8M | $69.9M | $93.5M | |
| Total Assets | $39.1M | $106.1M | $123.8M | $109M | $143.3M | |
| Current Liabilities | $10.7M | $8.1M | $17.4M | $20.3M | $27.3M | |
| Total Liabilities | $272.7M | $8.6M | $20.3M | $31.5M | $43.7M | |
| Total Equity | -$233.6M | $97.4M | $103.4M | $77.5M | $99.5M | |
| Total Debt | $98.6M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $14.2M | $25.6M | $34.7M | $6.6M | $9.7M | |
| Cash From Investing | -$7.9M | -$9.7M | -$13.9M | -$2.3M | -$2.7M | |
| Cash From Financing | -$8M | -$43.1M | -$1.4M | -$579K | -- | |
| Free Cash Flow | $6.2M | $16M | $23.8M | $4.3M | $7M | |
ENFN
Sector
Market Cap
$1B
$91.6M
Price % of 52-Week High
93.81%
60%
Dividend Yield
0%
0%
Shareholder Yield
--
0.82%
1-Year Price Total Return
19.03%
-15.91%
Beta (5-Year)
--
0.910
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$11.18
200-day SMA
Buy
Level
$9.55
Bollinger Bands (100)
Buy
Level
9.6 - 11.22
Chaikin Money Flow
Sell
Level
-1.7M
20-day SMA
Sell
Level
$11.25
Relative Strength Index (RSI14)
Sell
Level
45.10
ADX Line
Buy
Level
26.17
Williams %R
Buy
Level
-90.4762
50-day SMA
Buy
Level
$11.01
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
28.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.8204)
Buy
CA Score
(Annual)
Level (0.3973)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.6201)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. The products and services that comprise its solution are designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. It generates maximum revenue from the Americas, followed by Asia Pacific and Europe, the Middle East, and Africa.
Stock Forecast FAQ
In the current month, ENFN has received 0 Buy ratings 6 Hold ratings, and 0 Sell ratings. The ENFN average analyst price target in the past 3 months is $10.93.
-
Where Will Enfusion Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enfusion share price will drop to $10.93 per share over the next 12 months.
-
What Do Analysts Say About Enfusion?
Analysts are divided on their view about Enfusion share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enfusion is a Sell and believe this share price will rise from its current level to $9.64.
-
What Is Enfusion's Price Target?
The price target for Enfusion over the next 1-year time period is forecast to be $10.93 according to 6 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is ENFN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enfusion is a Hold. 6 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ENFN?
You can purchase shares of Enfusion via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enfusion shares.
-
What Is The Enfusion Share Price Today?
Enfusion was last trading at $11.09 per share. This represents the most recent stock quote for Enfusion. Yesterday, Enfusion closed at $11.07 per share.
-
How To Buy Enfusion Stock Online?
In order to purchase Enfusion stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
